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At a Glance Commentary 
The present study is the first to investigate the effect of menopause on lung function in a 
large, longitudinal and population-based survey. We analyzed the decline of forced vital 
capacity and forced expiratory volume in one second as related to menopausal status. The 
study population is a hormonally well-defined group of women, aggregated by latent class 
analysis on measurements of follicle stimulating hormone and luteinizing hormone as well as 
questionnaire data. Linear mixed effects models showed that postmenopausal women and 
women in the menopausal transition are associated with a steeper decline in lung function, 
beyond the age related decline, compared to nonmenopausal women. Our findings are 
relevant for clinical practice and health care professionals should be aware that women 
undergoing the menopausal transition are at risk of accelerated lung function decline.  
 
Online data supplement 
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org  
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Abstract 
Rationale: Menopause is associated with changes in sex hormones, which affect immunity, 
inflammation, and osteoporosis and may impair lung function. Lung function decline has not 
previously been investigated in relation to menopause. 
 
Objectives: To study whether lung function decline, assessed by forced vital capacity and 
forced expiratory volume in one second, is accelerated in women who undergo menopause. 
 
Methods: The population-based longitudinal European Community Respiratory Health 
Survey provided serum samples, spirometry and questionnaire data about respiratory and 
reproductive health from three study waves (N=1438). We measured follicle stimulating 
hormone and luteinizing hormone and added information on menstrual patterns, to determine 
menopausal status using latent class analysis. Associations with lung function decline were 
investigated using linear mixed effects models, adjusting for age, height, weight, packyears, 
current smoking, age at completed full-time education, spirometer and including study center 
as random effect. 
 
Measurements and Main Results: Menopausal status was associated with accelerated lung 
function decline. The adjusted mean forced vital capacity decline was increased by -10.2 
ml/yr (95% Confidence interval -13.1 to -7.2) in transitional women and -12.5 ml/yr (-16.2 to 
-8.9) in postmenopausal women, compared to women menstruating regularly. The adjusted 
mean forced expiratory volume in one second decline increased by -3.8 ml/yr (-6.3 to -2.9) in 
transitional women and -5.2 ml/yr (-8.3 to -2.0) in postmenopausal women. 
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Conclusions: Lung function declined more rapidly among transitional and postmenopausal 
women, in particular for forced vital capacity, beyond the expected age change. Clinicians 
should be aware that respiratory health often deteriorates during reproductive aging. 
 
Key words 
Latent class analysis; lung function decline; menopause; reproductive aging; sex hormones; 
 
Word count abstract 
250 
 
Abbreviations used 
BLUP: Best Linear Unbiased Prediction 
BMI: Body Mass Index 
CI: Confidence Interval 
FEV1: Forced Expiratory Volume In One Second 
FSH: Follicle Stimulating Hormone 
FVC: Forced Vital Capacity 
LH: Luteinizing Hormone  
OBS: Observations 
SD: Standard Deviation
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INTRODUCTION 
The non-reproductive phase of a woman’s life begins with menopause (1). Cessation of 
menstruations may be accompanied by lack of energy, hot flushes, vaginal discharge, 
insomnia, osteoporosis and an increased risk of developing chronic conditions like diabetes 
and cardiovascular disease (2-6). Menopause is associated with profound changes in the 
activity of the hypothalamo-pituitary-gonadal axis: as 17β-estradiol production in the ovaries 
ceases, follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations rise 
(7, 8). Low levels of 17β-estradiol are associated with increased systemic inflammation and 
inflammation in the lungs (9-16). The inflammation markers C-reactive protein and 
Interleukin-6 are inversely associated with forced vital capacity (FVC) and forced expiratory 
volume in one second (FEV1) (17, 18). These findings point towards a possible association 
between menopause and increased lung function decline. Given today’s life expectancy far 
beyond the age of menopause, understanding how to maintain good health and quality of life 
in later years is important (1, 19-22). The role of sex hormones in respiratory health is 
increasingly acknowledged (23-32). However, potential changes in respiratory health as 
related to reproductive aging in women are still poorly understood (23, 33, 34). A recent 
longitudinal analysis of a large population based survey showed higher incidence of new-
onset asthma and increase in respiratory symptoms as related to menopause (28). Potential 
changes in lung function with menopause have only been addressed in cross-sectional 
analyses: One population-based study of women aged 45 to 55 years, not using hormone 
replacement therapy, found lower lung function in postmenopausal women compared to 
women who still had regular menstruations (27). A recent study from the UK Biobank found 
an association between cessation of menstruation and lower lung function, whereas another 
study saw no independent effect of menopause on FVC and FEV1 levels (35, 36). It has been 
reported that lifestyle factors such as smoking may be more detrimental after menopause, 
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while some hormone replacement therapy regimens appear to be associated with higher lung 
function in postmenopausal women (37-39). Whether obesity impacts on respiratory health in 
menopause is not known, although sex hormones and body fat mass are interrelated (40, 41) 
and effect modification of BMI on the role of hormone replacement therapy is suggested in 
cross-sectional studies (42). The aim of the present study was to investigate the association of 
menopausal status with decline in lung function over a 20-year period, using data from a 
large European, population-based cohort. Some of the results of this study have been 
previously reported in the form of an abstract to the European Respiratory Society annual 
congress (43).  
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METHODS 
Study population 
The European Respiratory Health Survey (ECRHS) is an international multicenter study 
including three waves, ECRHS 1 in 1991-1994, ECRHS 2 in 1998-2002 and ECRHS 3 in 
2010-2012, and is described in detail at http://www.ecrhs.org. The age range at baseline was 
25 to 48 years and the median observation time for women participating in all three waves 
was 19.7 (17.9 - 22.4) years. The present study includes 19 centers in Europe (see Table E1 
in the online data supplement). The examinations included an interviewer-led questionnaire, 
spirometry and serum sampling. At ECRHS 2 and 3 women additionally answered 
standardized questionnaires on women’s health. For 2484 women, serum samples from 
ECRHS 2 and/or 3 were analyzed for FSH and LH (see online data supplement). Inclusion 
criteria are presented in Figure 1. Ethical approval was obtained from the appropriate ethics 
committee and each participant provided informed written consent. 
 
Figure 1. Study population with inclusion criteria (*height and packyears) 
 
Classification according to menopausal status 
Every woman contributed with up to three observations (ECRHS 1, 2 and/or 3, Nobs=3295). 
We attributed each observation separately to a menopausal status, at the same time as the 
pulmonary function tests were conducted. At baseline we included only nonmenopausal 
women, excluding women who retrospectively reported their last period more than one year 
before baseline. To determine menopausal status at ECRHS 2 and 3 we performed latent 
class analysis in order to identify subgroups within our population, based on menopause 
related factors such as hormone levels and presence and/or regularity of menstruations (44, 
45). Latent class analysis is commonly used in medical research to classify subjects by 
selected characteristics (>2000 publications listed on www.PubMed.gov). The number of 
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classes was restricted to three, retrospectively labeled: nonmenopausal, transitional and 
postmenopausal. Observations were assigned class-memberships based on response 
probabilities (see Table E2 in the online data supplement).  The algorithm, grouping the most 
similar observations, was repeated 30 times with a maximum of 10.000 iterations. The 
included categorical variables were FSH in quintiles, LH in quintiles and menstrual status as 
reported by participants (see Table E2 in the online data supplement). Each participant was 
present either in one, two or all three classes, representing the reproductive stage at different 
waves. 
 
Outcomes 
FVC and FEV1 were recorded following standardized methods (46, 47). The spirometers that 
were used are presented in Table E1 in the online data supplement.  
 
Statistical analysis 
Data of all three waves was modeled by linear mixed effects models, allowing for random 
intercepts (48). By including spirometric measurements and an interaction term of the 
menopausal status with age, we determined the lung function decline defined as the slope of 
change in lung capacity, which can be interpreted as the mean annual decline [ml/yr] 
associated with each menopausal status. We adjusted for fixed effects of age, weight, 
packyears, current smoking and type of spirometer at each wave, as well as height at baseline 
and age at completed full time education as a socioeconomic proxy, which if missing (6.0%) 
was imputed as the population mean. Missing age (3.8%) and weight (9.4%) were included as 
age and weight at a different wave plus the mean increase during follow-up. The participant’s 
id number, nested in the respective study center, was accounted for as random effect. 
Stratified analyses were performed among never-smokers, ever-smokers and BMI categories 
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according to the World Health Organization. To investigate whether results were driven by a 
history of asthma, or gynecological disorders such as polycystic ovary syndrome, 
endometriosis, surgical menopause (reported at ECRHS 2 or 3) or premature menopause (<40 
years), we performed sensitivity analysis within the respective subgroups without these 
conditions. We further tested potential heterogeneity between study centers and an alternative 
model, accounting for change in height over the study period. Analyses were performed using 
R (Version 3.1.0, The R Foundation for Statistical Computing).  
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RESULTS 
Characteristics of the subjects at baseline are presented in Table 1. The class conditional 
probabilities and standard errors for the class membership, determined by latent class 
analysis, can be found in Table E2 in the online data supplement. 
Table 1. Characteristics of the study population at baseline (n=13691) 
Median (5
th
, 95
th
 percentile) 
Age [yr] 36.2 (26.8, 45.0) 
Height [m] 1.64 (1.52, 1.75) 
Weight [kg] 61 (50, 85) 
BMI [kg/m
2
] 22.6 (18.8, 31.2) 
Packyears 1.0 (0.0, 24.0) 
Current smoking, n (%) 438 (32) 
Year of PFT
1
 1992 (1991, 1993) 
Observation time [yr] 19.7 (18.5, 21.0) 
FVC [L] 3.85 (2.94, 4.80) 
FEV1 [L] 3.19 (2.37, 3.96) 
Delta FVC
2
 [ml/yr] 25.8 (2.4, 53.6) 
Delta FEV1
2
 [ml/yr] 33.4 (10.7, 56.9) 
1Ntotal=1438, baseline observations for 69 women were incomplete and therefore excluded (follow-up 
observations of these women were included) 
2 Pulmonary function test 
3Annualized change over follow-up 
 
The included 1438 women provided a total of 3295 complete observations (pulmonary 
function tests) including data on menopausal status and covariates (up to three observations 
per woman). The nonmenopausal class included 60% (nobs=1992), the transitional class 18% 
(nobs=583) and the postmenopausal class 22% (nobs=720) of the observations. The mean age 
was 39 years in the nonmenopausal, 53 years in the transitional and 56 years in the 
postmenopausal class (Table 2). Weight and BMI were highest in the transitional class (Table 
2). 
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Table 2. Characteristics of the observations by menopausal class, mean (SD) 
 
Nonmenopausal 
(nobs =1992) 
Transitional 
(nobs =583) 
Postmenopausal 
(nobs =720) 
Age [yr] 38.8 (6.8) 52.8 (8.2) 55.7 (5.4) 
Height [m] 1.64 (0.07) 1.63 (0.07) 1.63 (0.07) 
Weight [kg] 65.2 (12.6) 71.7 (15.2) 69.3 (12.5) 
BMI [kg/m
2
] 24.2 (4.5) 26.8 (5.4) 26.0 (4.4) 
Packyears 6.2 (10.3) 9.2 (16.5) 9.5 (17.9) 
Current smoking, n (%) 581 (29) 120 (21) 115 (16) 
FVC [L] 3.81 (0.58) 3.41 (0.60) 3.35 (0.54) 
FEV1 [L] 3.11 (0.50) 2.64 (0.53) 2.55 (0.45) 
FSH [IU/L] 9.3 (9.9) 56.8 (40.9) 146.9 (80.0) 
LH [IU/L] 5.8 (5.7) 20.1 (10.0) 35.5 (11.0) 
 
Figures 2 and 3 show the best linear unbiased predictions (BLUP´s) for FVC and FEV1 of the 
whole population, obtained by adding together the population predictions (based on the fixed 
effects estimates) and the estimated contributions of the random effects (48). Both curves 
show a negative increase in slope when a large proportion of women enter the transitional or 
menopausal stage.  
 
Figure 2. Best linear unbiased predictions for FVC of the study population (n=1438) according to the specified linear 
mixed effects model, including 95%CI and population distribution by menopausal class (The dotted line, as visual aid 
continues the initial slope).   
Figure 3. Best linear unbiased predictions for FEV1 of the study population (n=1438) according to the specified linear 
mixed effects model, including 95%CI and population distribution by menopausal class (The dotted line, as visual aid 
continues the initial slope). 
 
The mean age dependent lung function decline for all groups was -15.9 ml/yr (95% CI -18.2 
to -13.6) for FVC and -24.0 ml/yr (-25.9 to -22.0) for FEV1. The interaction term of 
menopausal status with age showed that the mean FVC decline was additionally increased by 
-10.2 ml/yr (-13.1 to -7.2) for women classified as transitional and -12.5 ml/yr (-16.2 to -8.9) 
for women classified as postmenopausal, compared to women menstruating regularly. The 
mean FEV1 decline additionally increased by -3.8 ml/yr (-6.3 to -2.9) for women classified as 
transitional and by -5.2 ml/yr (-8.3 to -2.0) for women classified as postmenopausal.  
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Current smoking was significantly associated with FEV1 decline [-29.3 ml (-54.0 to -4.7)] 
compared to former smoking and lifelong non-smoking, whereas packyears were 
significantly associated with both FEV1 decline [-2.3 ml/packyear (-3.0 to -1.5)] and FVC 
decline [-1.0 ml/packyear (-1.9 to -0.1)]. The results for other covariates of the primary 
analysis are presented in Tables E3 and E4 in the online data supplement. 
Analysis of FVC decline as related to menopause and stratified according to BMI at ECRHS 
3 showed a higher age related decline (Figure 4) and indicated a smaller menopause related 
decline with increasing BMI (pinteraction<0.01 for transitional women and pinteraction<0.001 for 
postmenopausal women) (Figure 5). Ever smokers indicated a higher age related decline and 
higher menopause related decline than never smokers. For FEV1 we observed a similar but 
less distinct pattern (Figure 4 and Figure 5). 
 
Figure 4. Age related lung function decline by smoking and BMI for the study population, ml/yr 
Figure 5. Menopause related lung function decline by smoking and BMI for the menopausal class, ml/yr 
 
The sensitivity analysis showed that the results were not driven by a history of asthma, by 
gynecological disorders, by hypertension or cardiovascular disorders, or by surgical or 
premature menopause (data not given). Results were consistent for individual centers with 
sufficient participants (Galdakao, Albacete, Grenoble, Paris, Reykjavik, Bergen, Umeå and 
Uppsala).  
Height changed over the study period. The age related decline in height was -0.23 mm/yr 
(95% CI -0.38 to -0.08). Women in the menopausal transition had an additional decline of -
0.62 mm/yr (-0.79 to -0.05) and the postmenopausal class an additional decline of -0.77 
mm/yr (-0.98 to -0.06). The alternative model accounting for change in height showed a 25% 
reduced, yet still significant, decline in FVC for both the transitional [-7.7 ml/yr (-10.6 to -
4.7)] and the postmenopausal class [-9.0 ml/yr (-12.7 to -5.5)], compared to the 
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nonmenopausal class. The decline for FEV1 was reduced by circa 50% and not significant 
after such adjustment (transitional class: -2.1 ml/yr (-4.7 to 0.3), postmenopausal class: -2.6 
ml/yr (-5.8 to 0.5).  
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DISCUSSION 
This population-based study of 1438 women aged 25-48 years from nine European countries 
over 20 years with repeated spirometry, hormone measurements and questionnaire data, 
found that lung function declined more rapidly in women who were transitional or 
postmenopausal, as compared to women who were nonmenopausal. To our knowledge, this is 
the first longitudinal population-based study that investigates lung function decline in relation 
to menopause.  
The menopause related decline was more pronounced for FVC than for FEV1, which points 
towards a restrictive rather than an obstructive pattern. Stratified analyses and sensitivity 
analyses revealed that these findings were very robust. Effect modification by BMI seems 
plausible, as circulating androgens are converted to estrogens in adipose tissue. Ever smokers 
show a suggested steeper decline in both age and menopause related impairment of lung 
function, possibly because of a combined effect of smoking on the lungs and its anti-
estrogenic effects. Sensitivity analyses in women without a history of asthma, surgical 
menopause or gynecological disorders, showed similar and statistically significant results.  
We used latent class analysis to define the menopausal status rather than fixed cut-offs, as 
this type of analysis accounts better for the underlying biology and the information gathered 
from the participants. Clustering of the most similar observations forms the latent classes, and 
the multivariate and repetitive nature of the classification process allows for a dynamic 
grouping based on maximum likelihood criteria. We restricted classification to three classes 
as the data favored more classes by a marginally better fit, yet it supported a structure of two 
clearly defined classes (nonmenopausal and postmenopausal), as well as a more 
heterogeneous class representing different stages within the menopausal transition. The 
transitional class might include a minority of postmenopausal and nonmenopausal women. 
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Hormone levels of women above 60 years who were still categorized as transitional are on 
average lower than in women categorized as postmenopausal. The trajectories of FSH over 
the menopausal transition are not uniform across the population; e.g. women with a higher 
BMI or expressed sexuality are more likely to show a slower increase and lower 
postmenopausal level of FSH (49-51). These women are most likely postmenopausal, 
however hormonally they are more similar to the transitional class, as determined by the 
latent class analysis (7, 8). The heterogeneity of the transitional class might dilute 
associations slightly.  
Hormonal changes in menopause, linked to complex biological events might contribute to the 
demonstrated acceleration in lung function decline with menopause. One possible mechanism 
is systemic inflammation, which is associated with menopausal hypoestrogenism and 
impaired lung function. The way 17β-estradiol affects inflammation depends strongly on the 
type of inflammatory or immunogenic stimulus, the involved cell types, the target organ’s 
specific microenvironment and metabolism, leading to different anti- and proinflammatory 
effects (10, 52). Animal models suggest that low levels of 17β-estradiol might amplify 
inflammation and higher levels might attenuate it (11, 12). In rats and mice, surgically 
induced menopause enhances pleural exudation, leukocyte migration and lung 
myeloperoxidase activity amongst others (13, 14). Ovariectomy is further associated with 
increased levels of inflammatory markers, which decreased after 17β-estradiol substitution 
(13, 14). A comprehensive review concluded that in all available inflammatory models of the 
lung, 17β-estradiol was demonstrated to have an anti-inflammatory effect (10). 
Further, hypoestrogenism plays a critical role in osteoporosis, which results in reduced height 
of the thoracic vertebrae which may mechanically reduce the expansion of the thoracic cage 
during inspiration and place the diaphragm in a suboptimal position (53, 54). Our findings 
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suggested that the accelerated decline related to menopause was in part explained by 
osteoporosis, as accounting for change in height attenuated the associations of menopause 
with decline in FVC as well as FEV1.  
Strengths of the present study are the availability of repeatedly measured lung function and 
hormone measurements as well as interview/questionnaire data for large population samples. 
A unique window of opportunity was taken advantage of, as the study subjects were aged 25-
48 years at baseline and most women went through the age of the menopausal transition 
during the 20-year follow-up. Hormone measurements at two time points are a major strength 
of this analysis, as well as the use of latent class analyses to define menopause based on both 
hormone measurement and questionnaire information. The crude definition of menopause at 
baseline, only based on questionnaire data, is a weakness of the study that may have 
introduced minor non-differential error and thus attenuated true results. The outcomes of the 
study, objectively measured lung function parameters are a strength and spirometric 
measurement error is unlikely to be related to menopausal status. The change in spirometers 
between surveys is accounted for in the analyses, however, it is possible that a residual non-
differential measurements error may have attenuated the true results. The multinational and 
multi-centric design of the study allows for high external validity and the consistency across 
geographic and cultural borders suggests biologic explanatory mechanism rather than 
confounding by sociocultural factors.  
Conclusions 
The present study shows that menopause was associated with an accelerated decline in lung 
function, beyond the expected age related decline. This was most pronounced for FVC. The 
results were consistent across subgroups and independent of smoking history. The effect size 
for FEV1 was comparable to smoking 20 cigarettes per day for two years, and for FVC to 
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smoking 20 cigarettes per day for ten years. The mechanisms underlying the associations 
between reproductive aging and respiratory health need to be further investigated. Future 
studies should address potential beneficial effects of hormone replacement therapy. The 
results from the present study should be taken into account, as they are highly relevant for the 
health and quality of life of a large and steadily increasing number of women. 
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Figure 1. Study population with inclusion criteria (*height and packyears)  
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Figure 2. Best linear unbiased predictions for FVC of the study population (n=1438) according to the 
specified linear mixed effects model, including 95%CI and population distribution by menopausal class (The 
dotted line, as visual aid continues the initial slope).  
Figure 2  
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Figure 3. Best linear unbiased predictions for FEV1 of the study population (n=1438) according to the 
specified linear mixed effects model, including 95%CI and population distribution by menopausal class (The 
dotted line, as visual aid continues the initial slope).  
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Figure 4. Age related lung function decline by smoking and BMI for the study population, ml/yr  
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479x164mm (72 x 72 DPI)  
 
 
Page 28 of 36
  
 
 
Figure 5. Menopause related lung function decline by smoking and BMI for the menopausal class, ml/yr  
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ONLINE DATA SUPPLEMENT 
 
Hormone measurements 
At ECRHS 2 the levels of FSH and LH in the serum samples were determined by 
chemiluminescence in an Elecsys 2010 analyzer from Roche Diagnostics (Germany) at the 
Hôpital Xavier Bichat in Paris, France. At ECRHS 3 we determined FSH and LH levels using 
enzyme-linked immunosorbent assays provided by Demeditec Diagnostics, (Germany). All 
pipetting steps were executed fully automated on a liquid-handling robot from Hamilton 
Robotics using the protocol 4Elisa at the Core Facility for Metabolomics of the University of 
Bergen, Norway (www.uib.no/metabolomics). For FSH, the between day coefficient of 
variation was 7.0% and accuracy was 106%, for LH respectively 8.6% and 85%. 
 
Menopausal status 
Methods: At ECRHS 2 the menstrual status was obtained from the answers to the following 
questions: “Are your periods regular?”  (Alternatives: “Yes”, “No, they have never been 
regular”, “No they have been irregular for a few months”) and “Why did your periods stop?” 
(Alternatives: “Naturally”, “Because of surgery” and “Other”; and at ECRHS 3: “Do you 
have regular periods?” (Alternatives: “Yes”, “No, they have never been regular”, “No they 
have been irregular for a few months” and “No, my periods have stopped”).  
 
Results: At ECRHS 2, 52% (n=586) of the participants were categorized as nonmenopausal, 
28% (n=311) as transitional and 20% (n=223) as menopausal. At ECRHS 3, 26% (n=367) of 
the participants were categorized as nonmenopausal, 29% (n=409) as transitional and 46% 
(n=651) as menopausal. A reversal of menopausal status was indicated in the latent class 
analysis in a few cases (4%). Excluding these women from the analysis did not alter the 
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results. We kept the observations in the primary analysis with the corresponding class 
originally attributed by the latent class analysis. 
 
Pulmonary function data 
Pulmonary function data, including hormone measurements and a complete set of covariates 
was available at baseline for 1369 women (95%), at ECRHS 2 for 866 women (60%) and 
ECRHS 3 for 1060 women (74%).  Of the included women 71% provided measurements at 
all three waves, 28% at two waves and 2% at one wave. 
 
Table E1. Spirometers used by center and wave 
Centre ECRHS 1 ECRHS 2 ECRHS 3 
Aarhus (DK) Vitalograph spiro - NDD Easyone 
    
Hamburg (DE) Jaeger pneum Jaeger pneum NDD Easyone 
Erfurt (DE) Jaeger pneum Jaeger pneum NDD Easyone 
    
Galdakao (ES) Biomedin spiro Biomedin spiro NDD Easyone 
Albacete (ES) Biomedin spiro Biomedin spiro NDD Easyone 
Huelva (ES) Biomedin spiro Biomedin spiro NDD Easyone 
    
Bordeaux (FR) Vitalograph spir Vitalograph spir NDD Easyone 
Grenoble (FR) Biomedin spiro Biomedin spiro NDD Easyone 
Montpellier (FR) Biomedin spiro Biomedin spiro NDD Easyone 
Paris (FR) Biomedin spiro Biomedin spiro NDD Easyone 
    
Reykjavik (IS) SensorMedics spiro SensorMedics spiro NDD Easyone 
    
Bergen (NO) SensorMedics spiro SensorMedics spiro NDD Easyone 
    
Gothenburg (SE) SensorMedics spiro SensorMedics spiro NDD Easyone 
Umea (SE) SensorMedics spiro SensorMedics spiro NDD Easyone 
Uppsala (SE) SensorMedics spiro SensorMedics spiro NDD Easyone 
    
Tartu (EE) Jaeger pneum Jaeger pneum NDD Easyone 
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Table E2. Class conditional probabilities and standard errors for the latent class analysis 
First follow-up (ECRHS 2) Second follow-up (ECRHS 3) 
Group Nonmenopausal Transitional Menopausal Nonmenopausal Transitional Menopausal 
F
S
H
 q
u
in
ti
le
s 1st 41.6 (2.8) 0.0 (0.0) 0.0 (0.0) 77.1 (2.5) 0.0 (0.0) 0.5 (0.4) 
2nd 33.0 (2.3) 15.3 (2.7) 0.0 (0.0) 22.9 (2.5) 48.9 (4.2) 0.0 (0.0) 
3rd 25.0 (2.2) 22.3 (3.0) 0.0 (0.0) 0.0 (0.0) 36.3 (3.7) 20.9 (2.7) 
4th 0.4 (2.3) 62.4 (3.7) 1.6 (3.2) 0.0 (0.0) 14.8 (3.7) 34.6 (2.5) 
5th 0.0 (0.0) 0.0 (0.0) 98.4 (3.2) 0.0 (0.0) 0.0 (0.0) 44.0 (2.7) 
L
H
 q
u
in
ti
le
s 1st 39.8 (2.4) 2.0 (2.4) 0.0 (0.0) 77.2 (2.5) 0.6 (0.6) 0.0 (0.0) 
2nd 33.8 (2.3) 11.5 (2.7) 0.0 (0.0) 18.0 (2.2) 43.2 (3.3) 6.4 (1.5) 
3rd 25.2 (2.2) 24.7 (3.0) 0.0 (0.0) 2.3 (0.9) 32.6 (2.9) 21.9 (2.0) 
4th 1.3 (0.9) 47.8 (4.1) 22.7 (2.9) 0.0 (0.0) 14.9 (2.5) 34.6 (2.2) 
5th 0.0 (0.0) 14.1 (2.5) 77.4 (2.9) 2.5 (1.1) 8.7 (2.1) 37.2 (2.2) 
M
en
se
s Regular 85.3 (1.7) 65.1 (3.4) 9.2 (2.0) 70.5 (2.8) 6.5 (1.8) 1.4 (0.6) 
Irregular 6.4 (1.2) 13.6 (2.1) 17.5 (2.6) 17.8 (2.3) 15.4 (2.3) 4.8 (1.1) 
Stopped 8.3 (1.3) 21.3 (2.8) 73.3 (3.0) 11.8 (2.0) 78.1 (2.8) 93.8 (1.3) 
 
 
Table E3. Determinants of decline of forced vital capacity  
Mean (95% CI)
4
 p-Value 
Age
1
 [ml/yr] -15.9 (-18.2 to -13.7)  < 0.001 
Height at baseline [ml/cm] 52.3 (48.6 to 55.9)  < 0.001 
Weight [ml/kg] -6.5 (-7.8 to -5.3)  < 0.001 
Packyears [ml/packyear] -1.0 (-1.9 to -0.1)  0.04 
Current smoking
2
 [ml] -9.4 (-38.1 to 19.3)  0.52 
Education
3 
[ml/yr] 1.1 (-2.9 to 5.0)  0.60 
1Centered at median 
2Current smoking compared to former and never smokers 
3Age at completed full-time education 
4Linear mixed effect model, intercept -4.6 L (-5.2 to -4.0) 
 
Table E4. Determinants of decline of forced expiratory volume in one second  
Mean (95% CI)
4
 p-Value 
Age
1
 [ml/yr] -24.2 (-26.2 to -22.3)  < 0.001 
Height at baseline [ml/cm] 37.2 (34.1 to 40.3)  < 0.001 
Weight [ml/kg] -4.3 (-5.4 to -3.2)  < 0.001 
Packyears [ml/packyear] -2.2 (-3.0 to -1.4)  0.04 
Current smoking
2
 [ml] -29.3 (-54.0 to -4.7)  0.02 
Education
3 
[ml/yr] 1.2 (-2.2 to 4.5)  0.50 
1Centered at median 
2Current smoking compared to former and never smokers 
3Age at completed full-time education 
4Linear mixed effect model, intercept -3.0 L (-3.5 to -2.5) 
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Financial support for ECRHS I: The following grants helped to fund the local studies. 
Estonia:  Estonian Science Foundation, grant no 1088, France:  Ministère de la Santé, Glaxo 
France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Région Languedoc-
Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre delegué de la santé, RNSP, 
France; GSF, Germany: Bundesminister für Forschung und Technologie, Norway:  
Norwegian Research Council project no. 101422/310; Spain:  Fondo de Investigación 
Sanitaria ( #91/0016-060-05/E, 92/0319 and #93/0393), Hospital General de Albacete, 
Hospital General Juan Ramón Jiménez,   Dirección Regional de Salud Pública (Consejería de 
Sanidad  del Principado de Asturias), CIRIT (1997 SGR 00079) and Servicio Andaluz de 
Salud;  Sweden: The Swedish Medical Research Council, the Swedish Heart Lung 
Foundation, the Swedish Association against Asthma and Allergy; Switzerland: Swiss 
national Science Foundation grant 4026-28099;  
Financial Support for ECRHS II: Estonia: Tartu Estonian Science Foundation grant no 
4350, France: (All) Programme Hospitalier de Recherche Clinique—Direction de la 
Recherche Clinique (DRC) de Grenoble 2000 number 2610, Ministry of Health, Ministère de 
l’Emploi et de la Solidarité, Direction Génerale de la Santé, Centre Hospitalier Universitaire 
(CHU) de Grenoble, Bordeaux: Institut Pneumologique d’Aquitaine; Grenoble:  Comite des 
Maladies Respiratoires de l’Isere; Montpellier: Aventis ( France), Direction Regionale des 
Affaires Sanitaires et Sociales Languedoc-Roussillon; Paris: Union Chimique Belge- Pharma 
(France),Aventis (France), Glaxo France,; Germany: Erfurt GSF—National Research Centre 
for Environment and Health, Deutsche Forschungsgemeinschaft (grant code, FR1526/1-1) 
Hamburg: GSF—National Research Centre for Environment and Health, Deutsche 
Forschungsgemeinschaft (grant code, MA 711/4-1) Iceland: Reykjavik, Icelandic Research 
Council, Icelandic University Hospital Fund; Norway: Bergen: Norwegian Research Council, 
Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway Research Fund;  
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Spain: Fondo de Investigación Santaria (grant codes, 97/0035-01,99/0034-01 and 99/0034 
02), Hospital Universitario de Albacete, Consejeria de Sanidad; Barcelona: Sociedad 
Española de Neumología y Cirugía Torácica, Public Health Service (grant code, R01 
HL62633-01), Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 
99/0034-02), Consell Interdepartamental de Recerca i Innovaci\o Tecnol\ogica (grant code, 
1999SGR 00241) Instituto de Salud Carlos III; Red de Centros de Epidemiología y 
SaludPública, C03/09, Red de Bases moleculares y fisiológicas de las Enfermedades 
Respiratorias,C03/011and Red de Grupos Infancia y Medio Ambiente G03/176;  Huelva: 
Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02); 
Galdakao: Basque Health Department Oviedo: Fondo de Investigaciones Sanitaria (97/0035-
02, 97/0035, 99/0034-01, 99/0034-02, 99/0034-04, 99/0034-06, 99/350, 99/0034--07), 
European Commission (EU-PEAL PL01237), Generalitat de Catalunya (CIRIT 1999 SGR 
00214), Hospital Universitario de Albacete, Sociedad Española de Neumología y Cirugía 
Torácica (SEPAR R01 HL62633-01) Red de Centros de Epidemiología y Salud Pública 
(C03/09), Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias 
(C03/011) and Red de Grupos Infancia y Medio Ambiente (G03/176);97/0035-01, 99/0034-
01, and99/0034-02); Sweden: Göteborg , Umea, Uppsala: Swedish Heart Lung Foundation, 
Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and 
Allergy Foundation, Swedish Cancer and Allergy Foundation, Swedish Council for Working 
Life and Social Research (FAS),Switzerland: Basel Swiss National Science Foundation, 
Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund;  
Financial Support for ECRHS III: Estonia: Tartu- SF0180060s09 from the Estonian 
Ministry of Education. France: (All) Ministère de la Santé. Programme Hospitalier de 
Recherche Clinique (PHRC) national 2010 ; Bordeaux: INSERM U897 Université Bordeaux 
segalen Grenoble: Comitee Scientifique AGIRadom 2011. Paris: Agence Nationale de la 
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Santé, Région Ile de France, domaine d’intérêt majeur (DIM) Germany : Erfurt: German 
Research Foundation HE 3294/10-1 Hamburg: German Research Foundation MA 711/6-1, 
NO 262/7-1 Iceland: Reykjavik, The Landspitali University Hospital Research Fund, 
University of Iceland Research Fund, ResMed Foundation, Vegagerðin (The Icelandic Road 
Administration (ICERA ) Norway: Norwegian Research Council, grant no 214123, Western 
Norway Regional Health Authorities grant no 911631, Bergen Medical Research Foundation.  
Spain: Fondo de Investigación Sanitaria (PS09/02457,  PS09/00716 09/01511) PS09/02185 
PS09/03190), Servicio Andaluz de Salud , Sociedad Española de Neumología y Cirurgía 
Torácica (SEPAR 1001/2010); Sweden: All centres were funded by The Swedish Heart and 
Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association 
against Lung and Heart Disease.Fondo de Investigación Sanitaria (PS09/02457 
Barcelona:Fondo de Investigación Sanitaria (FIS PS09/00716) Galdakao: Fondo de 
Investigación Sanitaria (FIS 09/01511) Huelva: Fondo de Investigación Sanitaria (FIS 
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